Theravance Biopharma Set to Release Q3 Earnings on November 10
Theravance Biopharma, Inc. is expected to announce its financial results for the third quarter of 2025 after the market closes on November 10, 2025. Analysts project the company will report a loss of ($0.03) per share along with revenues of approximately $19.89 million. Investors and analysts can access the latest insights during the earnings call scheduled for 5:00 PM ET on the same day.
Shares of Theravance Biopharma, traded under the ticker symbol TBPH on NASDAQ, opened at $14.75 on Friday. The stock has seen a slight decline of 0.8%. Its fifty-day moving average stands at $14.20, while the 200-day moving average is $12.08. The current market capitalization of Theravance Biopharma is approximately $742.81 million, with a price-to-earnings ratio of 61.46 and a beta of 0.07. Over the past year, the stock has fluctuated between a low of $7.90 and a high of $15.34.
In recent months, several institutional investors have adjusted their stakes in Theravance Biopharma. For instance, Tower Research Capital LLC increased its holdings by 18.5% during the second quarter, acquiring an additional 781 shares, bringing its total ownership to 5,013 shares valued at $55,000. Other notable transactions include AQR Capital Management LLC, which purchased a new stake valued at around $101,000, and Creative Planning, which acquired a position worth about $139,000 during the same quarter.
The trend among institutional investors remains strong, with approximately 99.10% of Theravance Biopharma’s stock held by such entities. This level of institutional ownership can often signal confidence in the company’s long-term prospects.
Theravance Biopharma is recognized for its focus on the discovery, development, and commercialization of organ-selective medicines. The company aims to innovate a new generation of small molecule drugs that address specific patient needs, particularly in the fields of inflammation and immunology. By leveraging insights and innovative strategies throughout its operations, Theravance Biopharma seeks to enhance its product offerings and improve patient outcomes.
For ongoing updates and insights into Theravance Biopharma and related companies, interested parties can subscribe to the daily email newsletter provided by MarketBeat.com for concise summaries of the latest news and analyst ratings.
